An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis.

J Mater Sci Mater Med

Biomaterials and Medical Devices Research Group, School of Pharmacy and Biomolecular Sciences, University of Brighton, Huxley Building, Lewes Road, Brighton, East Sussex, BN2 4GJ, UK,

Published: June 2014

Adsorbents designed with porosity which allows the removal of protein bound and high molecular weight uraemic toxins may improve the effectiveness of haemodialysis treatment of chronic kidney disease (CKD). A nanoporous activated carbon monolith prototype designed for direct blood contact was first assessed for its capacity to remove albumin bound marker toxins indoxyl sulphate (IS), p-cresyl sulphate (p-CS) and high molecular weight cytokine interleukin-6 in spiked healthy donor studies. Haemodialysis patient blood samples were then used to measure the presence of these markers in pre- and post-dialysis blood and their removal by adsorbent recirculation of post-dialysis blood samples. Nanopores (20-100 nm) were necessary for marker uraemic toxin removal during in vitro studies. Limited removal of IS and p-CS occurred during haemodialysis, whereas almost complete removal occurred following perfusion through the carbon monoliths suggesting a key role for such adsorbent therapies in CKD patient care.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033810PMC
http://dx.doi.org/10.1007/s10856-014-5173-9DOI Listing

Publication Analysis

Top Keywords

uraemic toxins
8
high molecular
8
molecular weight
8
blood samples
8
post-dialysis blood
8
removal
6
adsorbent monolith
4
monolith device
4
device augment
4
augment removal
4

Similar Publications

Pain is a frequent and disturbing symptom among hemodialysis patients. Protein-bound uremic toxins (PBUTs) are related to cardiovascular and overall mortality, and they are difficult to remove with current hemodialysis treatments. The PBUT displacers, such as furosemide, tryptophan, or ibuprofen, may be promising new strategies for improving their clearance.

View Article and Find Full Text PDF

Hemolytic-uremic syndrome (HUS) is a systemic complication of an infection with Shiga toxin (Stx)-producing enterohemorrhagic , primarily leading to acute kidney injury (AKI) and microangiopathic hemolytic anemia. Although free heme has been found to aggravate renal damage in hemolytic diseases, the relevance of the heme-degrading enzyme heme oxygenase-1 (HO-1, encoded by ) in HUS has not yet been investigated. We hypothesized that HO-1 also important in acute phase responses in damage and inflammation, contributes to renal pathogenesis in HUS.

View Article and Find Full Text PDF

Nephrotic syndrome (NS) represents a prevalent syndrome among various chronic kidney disease pathologies and is known for its higher severity and worse prognosis compared with chronic glomerulonephritis. Understanding its pathogenesis and identifying more effective treatment modalities have long been a concern of kidney specialists. With the introduction of the gut-kidney axis concept and the progress in omics technologies, alterations in the gut microbiota have been observed in primary and secondary NS.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the optimal way to create activated carbon from pineapple waste (leaves and peels) through pyrolysis and its combination with sodium alginate to form a bio-complex.
  • - Pyrolysis at 800 °C and activation with CO for 30 minutes resulted in high surface areas for the activated carbon, and while its microstructures showed some differences compared to commercial activated carbon, they had promising adsorption capabilities for uremic toxins.
  • - The research highlights the potential for developing cost-effective adsorbent products from agricultural waste, aiming to effectively target uremic toxins in simulated gastrointestinal conditions, fitting into a circular economy perspective.
View Article and Find Full Text PDF

Cardiovascular disease (CVD) is a major complication of chronic kidney disease (CKD), despite improvements in patient care. Vascular inflammation is a crucial process in the pathogenesis of CVD and a critical factor in the cardiovascular complications in CKD patients. CKD promotes a pro-inflammatory environment that impacts the vascular wall, leading to endothelial dysfunction, increased oxidative stress, and vascular remodeling.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!